Sugi Predict

Sugi Predict / Compounds / SCHEMBL475962

SCHEMBL475962

SCHEMBL475962

CCON[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 1/20 0.54
▸ MME P08473 6/20 0.52
▸ ACE P12821 6/20 0.52
▸ CPA1 P15085 1/20 0.52
▸ ACE2 Q9BYF1 1/20 0.52
▸ NAALAD2 Q9Y3Q0 1/20 0.50
▸ SLC7A5 Q01650 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ESR1 P03372 1/20 0.45
▸ ESR2 Q92731 1/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ CA12 O43570 1/20 0.44
▸ CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL475961 1.00 FOLH1 (0.54) FOLH1MMEACECPA1ACE2
SCHEMBL5017006 0.87 FPR2 (0.51) MMEACECPA1ACE2NAALAD2
SCHEMBL5017008 0.87 FPR2 (0.51) MMEACECPA1ACE2NAALAD2
SCHEMBL476060 0.84 FOLH1 (0.56) FOLH1MMEACECPA1ACE2
SCHEMBL476061 0.84 FOLH1 (0.56) FOLH1MMEACECPA1ACE2
SCHEMBL29664067 0.83 MME (0.56) FOLH1MMEACENAALAD2
SCHEMBL28216930 0.83 MME (0.56) FOLH1MMEACENAALAD2
SCHEMBL5841271 0.82 FOLH1 (0.49) FOLH1MMEACECPA1ACE2
SCHEMBL27775468 0.82 FOLH1 (0.48) FOLH1MMEACECPA1ACE2
SCHEMBL27775469 0.82 FOLH1 (0.48) FOLH1MMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055150-A1 GRAIL-1 PEPTIDE PRODUCTS AND METHODS UNIV MICHIGAN (US) 2026-02-26 — — US disclosed
EP-4680108-A1 PEPTIDE MULTIMER PRODUCTS AND METHODS The Regents of The University of Michigan (US) 2026-01-21 — — EP disclosed
US-20250263439-A1 HETERODIMERIC PEPTIDE REAGENTS AND METHODS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-08-21 — — US disclosed
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 — — EP disclosed
EP-4565333-A2 GRAIL-1 PEPTIDE PRODUCTS AND METHODS Regents of the University of Michigan (US) 2025-06-11 — — EP disclosed
US-12269900-B2 Inhibitors of β integrin-G protein α subunit binding interactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2025-04-08 — — US disclosed
US-20250073355-A1 CD44-BINDING PEPTIDE REAGENTS AND METHODS REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-03-06 — — US disclosed
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-02-13 — — US disclosed
WO-2025006976-A2 MRNA DISPLAY LIBRARIES AND METHODS OF USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2025-01-02 — — WO disclosed
EP-3666792-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-12-18 — — EP disclosed
WO-2011075393-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-06-23 — — WO disclosed
EP-2307037-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS Indiana University Research and Technology Corporation (US) 2011-04-13 — — EP disclosed
EP-2300037-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS Indiana University Research and Technology Corporation (US) 2011-03-30 — — EP disclosed
EP-2300035-A2 GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY Indiana University Research and Technology Corporation (US) 2011-03-30 — — EP disclosed
WO-2010148089-A1 GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-12-23 — — WO disclosed
WO-2010111617-A2 PARATHYROID HORMONE PEPTIDES AND PARATHYROID HORMONE-RELATED PROTEIN PEPTIDES AND METHODS OF USE VAN ANDEL RESEARCH INSTITUTE (US) 2010-09-30 — — WO disclosed
WO-2010071807-A1 AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-06-24 — — WO disclosed
WO-2010011439-A2 GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-01-28 — — WO disclosed
WO-2009155258-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 — — WO disclosed
WO-2009155257-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055150-A1 GRAIL-1 PEPTIDE PRODUCTS AND METHODS TP53, TP53BP1, DDIT3 FOLH1 916/4885MME 1514/4885ACE 4783/4885
US-20250263439-A1 HETERODIMERIC PEPTIDE REAGENTS AND METHODS ERBB2, EGFR, ERBB3 FOLH1 163/4885MME 1240/4885ACE 4080/4885
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 FOLH1 1266/4885MME 2976/4885ACE 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.